[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-426130-105":3,"doc-detail-426130-en":81,"detail-sidebar-cat-0-en-105":98},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-2-year-trial-of-metformin-to-reduce-frailty-in-older-adults-with-glucose-intolerance-short-research-abstract","A 2-YEAR TRIAL OF METFORMIN TO REDUCE FRAILTY IN OLDER ADULTS WITH GLUCOSE INTOLERANCE - Short research abstract","","Randomized, double-blinded, placebo-controlled clinical trial evaluates whether metformin improves health outcomes in older adults (≥65 years) with glucose intolerance. Participants randomized to 24 months of immediate-release metformin (500 mg/day titrated up to 2,000 mg/day) or placebo received diet and exercise counseling at baseline; those frail at baseline by Fried criteria were excluded. Frailty was tracked every 6 months using frailty index and Fried phenotype; GEE models assessed month-to-month change. Metformin showed no serious adverse events and reduced frailty progression by frailty index, suggesting a role in frailty prevention.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-2-year-trial-of-metformin-to-reduce-frailty-in-older-adults-with-glucose-intolerance-short-research-abstract/426130/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-2-year-trial-of-metformin-to-reduce-frailty-in-older-adults-with-glucose-intolerance-short-research-abstract/426130.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-19","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study design and who participated?","Question",{"text":63,"@type":64},"The study used a randomized, double-blinded, placebo-controlled design. Older adults (≥65 years) with glucose intolerance were enrolled, and participants frail at baseline by Fried criteria were excluded.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was metformin administered and what outcomes were measured?",{"text":68,"@type":64},"Metformin immediate-release was started at 500 mg/day and titrated to the maximum tolerated dose up to 2,000 mg/day, compared with matching placebo for 24 months. Frailty was measured every 6 months using a frailty index (deficit accumulation) and the Fried frailty phenotype.",{"name":70,"@type":61,"acceptedAnswer":71},"Did metformin improve frailty progression and was it safe?",{"text":72,"@type":64},"Metformin did not cause serious adverse events and showed no differences in adverse events between groups. It reduced frailty progression rate per month when assessed by the frailty index, while no difference was observed by Fried criteria.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},426130,1790769345,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",7,"482 Innovation in Aging, 2025, Vol. 9, No. S2  \nAbstract citation ID: igaf122.1648  \nA 2-YEAR TRIAL OF METFORMIN TO REDUCE FRAILTY IN OLDER ADULTS WITH GLUCOSE  \nINTOLERANCE  \nSara Espinoza1 Chen-pin Wang2, and Nicolas Musi1,  \n1. Cedars-Sinai Medical Center, Los Angeles, California, United States, 2. UT Health San Antonio, San Antonio, Texas, United States  \nIt has been postulated that metformin may extend healthspan but no long-term trials have been done in humans. We conducted a randomized, double-blinded, placebo-controlled clinical trial of metformin to reduce frailty in older adults (≥65 years) with glucose intolerance. Participants who were frail at baseline (Fried criteria) were excluded. Participants were randomized to 24 months of immediate release metformin (initiated at 500 mg/day and titrated to maximum tolerated dose up to 2,000 mg/day) or matching placebo. All participants received one session of diet and exercise counseling prior to initiation of study drug. The primary outcome was frailty as measured by the frailty index based on deficit accumulation model and frailty phenotype based on Fried criteria, which was assessed every 6 months. We conducted generalized estimating equations (GEE) models to  \nInnovation in Aging, 2025, Vol. 9, No. S2 483  \nexamine the change in frailty per month by frailty index and Fried criteria. 145 participants were randomized; intention to treat analysis included 141 participants who took at least one dose of study drug. At baseline, participants were 48% female, 35% Hispanic/Latino, and mean age was 71.8 ±5.3 years.  \nMetformin did not cause serious adverse events. There were no differences in adverse events by treatment group. Metformin led to a significant reduction in frailty progression rate per month assessed by frailty index compared to placebo (-0.0494 ±0.0216, 95%CI: -0.0918, -0.0071, p = 0.0222) . No difference was observed by Fried criteria (0.0116 ±0.0077, 95%CI: -0.0034, 0.0266, p = 0.1302) . Metformin administration to older adults with glucose intolerance may be useful for frailty prevention and extension of healthspan.","cbCais6jfmGk3yg9","https://ap.wps.com/l/cbCais6jfmGk3yg9","pdf",860352,"English","# Study design and participants\n## Treatment regimen and outcomes\n# Safety results\n## Frailty progression by frailty index and Fried criteria","[{\"question\":\"What was the study design and who participated?\",\"answer\":\"The study used a randomized, double-blinded, placebo-controlled design. Older adults (≥65 years) with glucose intolerance were enrolled, and participants frail at baseline by Fried criteria were excluded.\"},{\"question\":\"How was metformin administered and what outcomes were measured?\",\"answer\":\"Metformin immediate-release was started at 500 mg/day and titrated to the maximum tolerated dose up to 2,000 mg/day, compared with matching placebo for 24 months. Frailty was measured every 6 months using a frailty index (deficit accumulation) and the Fried frailty phenotype.\"},{\"question\":\"Did metformin improve frailty progression and was it safe?\",\"answer\":\"Metformin did not cause serious adverse events and showed no differences in adverse events between groups. It reduced frailty progression rate per month when assessed by the frailty index, while no difference was observed by Fried criteria.\"}]","A 2-YEAR TRIAL OF METFORMIN TO REDUCE FRAILTY IN OLDER ADULTS WITH GLUCOSE INTOLERANCE - Short research abstract | PDF",1790639470,5,{"code":4,"msg":82,"data":99},[100,104,108,112,116,120,123,128,133,136,140],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":114,"slug":115},"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},"Technology",50,"technology",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":121,"slug":122},40,"healthcare",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":126,"slug":127},8,"Research & Report",30,"research-report",{"id":129,"doc_module":4,"doc_module_name":25,"category_name":130,"show_sort_weight":131,"slug":132},9,"Religion & Spirituality",20,"religion-spirituality",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":134,"show_sort_weight":131,"slug":135},"World Cup","world-cup",{"id":137,"doc_module":4,"doc_module_name":25,"category_name":138,"show_sort_weight":137,"slug":139},10,"Lifestyle","lifestyle",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":97,"slug":143},19,"General","general"]